证券代码：838810 证券简称：春光药装 公告编号：2023-074 辽宁春光制药装备股份有限公司董事会战略委员会实施细则 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 审议及表决情况 本制度经辽宁春光制药装备股份有限公司第三届董事会第二十四次会议审 议通过，无需提交股东大会审议。 二、 制度的主要内容，分章节列示： 辽宁春光制药装备股份有限公司 董事会战略委员会实施细则 第一章 总则 第二章 人员组成 第三条 战略委员会成员由三名董事组成。 第四条 战略委员会委员由董事长、二分之一以上独立董事或者三分之一以 上董事提名，并由董事会选举产生。 第五条 战略委员会设主任委员（召集人）一名，由公司董事长担任。 第六条 战略委员会任期与董事会任期一致，委员任期届满，连选可以连任。 期间如有委员不再担任公司董事职务或不再具备相关法律法规及《公司章程》 所规定的任职资格，自动失去委员资格，并由董事会根据上述第三至第五条规 定补足委员人数。 第一条 为适应公司战略发展需要，增强公司核心竞争力，确定公司发展 ...

证券代码：838810 证券简称：春光药装 公告编号：2023-072 辽宁春光制药装备股份有限公司董事会提名委员会实施细则 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 审议及表决情况 二、 制度的主要内容，分章节列示： 辽宁春光制药装备股份有限公司 董事会提名委员会实施细则 第一章 总则 第一条 为完善辽宁春光制药装备股份有限公司（以下简称"公司"）法人 治理结构，增强董事会选举程序的科学性、民主性，优化董事会的组成人员结构， 公司特决定设立辽宁春光制药装备股份有限公司董事会提名委员会（以下简称 "提名委员会"）。 第二条 为使提名委员会规范、高效地开展工作，公司董事会根据《中华人 民共和国公司法》（以下简称"《公司法》"）、《辽宁春光制药装备股份有限 公司公司章程》（以下简称"《公司章程》"）等有关法律、法规和规范性文件 的有关规定，制订本实施细则。 第三条 提名委员会隶属于公司董事会，对董事会负责并报告工作。对于控 股股东推荐的董事候选人，提名委员会如认为其不适合任董事，有权予以拒绝。 ...

证券代码：838810 证券简称：春光药装 公告编号：2023-067 辽宁春光制药装备股份有限公司承诺管理制度 一、 审议及表决情况 本制度经辽宁春光制药装备股份有限公司第三届董事会第二十四次会议审 议通过，尚需提交股东大会审议 二、 制度的主要内容，分章节列示： 辽宁春光制药装备股份有限公司承诺管理制度 第一条 为加强对辽宁春光制药装备股份有限公司（以下简称公司）控股股 东、实际控制人、关联方以及公司的承诺及履行承诺行为的规范，切实保护中小 投资者合法权益，根据《中华人民共和国公司法》（以下简称《公司法》）、《中华 人民共和国证券法》（以下简称《证券法》）、《北京证券交易所股票上市规则（试 行）》（以下简称"《上市规则》"）及《公司章程》等有关法律法规、公司制度的 规定，结合公司实际情况，制定本制度。 第二条 公司控股股东、实际控制人及公司有关主体（以下简称承诺人）做 出的公开承诺应当具体、明确、无歧义、具有可操作性，并符合法律法规、部门 规章和业务规则的要求。公司应当及时将承诺人的承诺事项单独在符合《证券法》 规定的信息披露平台的专区披露。 第三条 公开承诺应当包括如下内容： （一）承诺的具体事项； 本 ...

Financial Performance - Operating revenue for the first nine months of 2023 was CNY 146,079,179.30, a decrease of 5.83% from CNY 155,119,768.26 in the same period of 2022[11]. - Net profit attributable to shareholders decreased by 42.56% to CNY 18,825,425.25 from CNY 32,774,990.97 year-on-year[11]. - Basic earnings per share dropped by 55.98% to CNY 0.27 from CNY 0.62 in the previous year[11]. - The company's net profit for the reporting period was CNY 18.68 million, a decrease of 43.01% year-on-year, mainly due to a decline in operating profit[15]. - Operating profit for the period was CNY 20.45 million, down 45.39% year-on-year, influenced by weaker pricing power in the pharmaceutical packaging equipment sector[14]. - The total comprehensive income for Q3 2023 was CNY 18,676,879.59, compared to CNY 32,774,990.97 in Q3 2022, reflecting a decline of about 43%[51]. Cash Flow - Cash flow from operating activities turned negative at CNY -889,402.76, a decline of 102.12% compared to CNY 42,009,832.91 in the same period last year[11]. - The cash inflow from operating activities for the first nine months of 2023 was CNY 132,667,232.20, compared to CNY 156,638,615.22 in the same period of 2022, a decrease of approximately 15.3%[52]. - The net cash outflow from operating activities for the first nine months of 2023 included CNY 66,947,274.93 for purchasing goods and services, compared to CNY 56,659,309.75 in the same period of 2022, an increase of approximately 18.5%[52]. - The net cash flow from operating activities for Q3 2023 was 4,738,607.04 CNY, a decrease of 76.1% compared to 19,637,657.33 CNY in Q3 2022[56]. - The company reported a total cash outflow of 131,597,623.05 CNY from operating activities, an increase of 25.3% from 105,194,430.01 CNY in Q3 2022[56]. Assets and Liabilities - Total assets increased by 6.15% to CNY 460,684,867.24 as of September 30, 2023, compared to CNY 433,992,572.72 at the end of 2022[11]. - The company's cash and cash equivalents decreased by 30.57% to CNY 123,868,801.30, primarily due to investments in a subsidiary's automation equipment production base[12]. - The total number of shares outstanding is 68,500,000, with 37.80% being unrestricted shares and 62.20% being restricted shares[19]. - The company has a total of CNY 61,088,749.02 in assets that are either pledged or restricted, accounting for about 13.26% of total assets[32]. - The company reported a total liability of CNY 89,533,145.22 in current liabilities, which is slightly up from CNY 86,938,588.19, showing an increase of about 2%[38]. Investments and Expenses - Cash outflow for purchasing fixed assets and other long-term assets was 94,807,571.17 CNY, compared to 1,622,268.50 CNY in the previous year, indicating a significant increase in capital expenditures[56]. - Research and development expenses for Q3 2023 were CNY 7,618,542.06, slightly down from CNY 7,635,919.21 in Q3 2022, indicating a marginal decrease[50]. - Total operating costs increased to CNY 131,989,352.59, up 15.5% from CNY 114,269,255.75 year-on-year[46]. Shareholder Information - The largest shareholder, Bi Chunguang, holds 26.72% of the shares, amounting to 18,301,266 shares[22]. - The total number of shareholders holding more than 5% of shares or among the top ten shareholders is 47,574,162, representing 69.47% of the total shares[22]. - There are no pledged or judicially frozen shares among the top ten shareholders[23]. Financial Management - The company's financial expenses decreased by 49.63% year-on-year to CNY 1.04 million, due to effective cost management[13]. - The company's credit impairment losses decreased by 48.52% year-on-year to CNY 3.20 million, reflecting improved collection of receivables[14]. - The cash flow from financing activities increased by 197.11% year-on-year to CNY 17.71 million, driven by increased short-term and long-term borrowings[15].

证券代码：838810 证券简称：春光药装 公告编号：2023-057 辽宁春光制药装备股份有限公司 关于向银行申请授信的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 为满足公司日常经营业务发展及需要，公司拟向中信银行股份有限公司抚顺 分行申请授信，授信有效期为 1 年，授信额度为 1000 万元，贷款性质为信用贷 款。公司实际控制人毕春光、边境提供连带责任保证担保。贷款的具体金额、期 限和相关条款以双方实际签署的贷款合同为准。 二、审议和表决情况 公司 2023 年 10 月 8 日召开第三届董事会第二十三次会议审议通过《关于公 司拟向中信银行申请授信的议案》，表决情况：同意 9 票，反对 0 票，弃权 0 票。 回避表决情况：议案无需回避表决。议案无需提交股东大会审议。 三、贷款的必要性 一、贷款基本情况 本次信用贷款是为满足公司正常生产经营和日常业务发展资金需要，有利于 公司持续稳定经营，促进公司发展，不会对公司经营产生不利影响，风险可控， 符合公司及全体股东的整体利益，是合理且必要的。 ...

证券代码：838810 证券简称：春光药装 公告编号：2023-056 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2023 年 10 月 8 日 2.会议召开地点：公司会议室 3.会议召开方式：现场及通讯方式 4.发出董事会会议通知的时间和方式：2023 年 10 月 5 日以书面通知方式发 出 5.会议主持人：毕春光 6.会议列席人员：监事及高级管理人员 辽宁春光制药装备股份有限公司 第三届董事会第二十三次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 （一）审议通过《关于公司拟向中信银行申请授信的议案》 1.议案内容： 为满足公司日常经营业务发展及需要，公司拟向中信银行股份有限公司抚顺 分行申请授信，授信有效期为 1 年，授信额度为 1000 万元，贷款性质为信用贷 款。公司实际控制人毕春光、边境提供连带责任保证担保。贷款的具体金额、期 限和相关条款以双方实际签署的贷款合同为准。 具体内容见公司在北京证券交易所指定信息披露平台（www.bse.cn）上披露 的《关于 ...

辽宁春光制药装备股份有限公司 关于公司全资子公司完成工商注册登记并取得营业执照的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 证券代码：838810 证券简称：春光药装 公告编号：2023-055 注册资本：300 万元 成立日期：2023 年 9 月 4 日 住所：辽宁省锦州市七里河工业园区 经营范围：一般项目：包装专用设备销售；机械零件、零部件销售；普通机 械设备安装服务；电子、机械设备维护（不含特种设备）；通用设备修理；专用 设备修理；电气设备修理；技术服务、技术开发、技术咨询、技术交流、技术转 让、技术推广。（除依法须经批准的项目外，凭营业执照依法自主开展经营活动） 一、基本情况 因经营发展需要，辽宁春光制药装备股份有限公司（以下简称"公司"）出资 设立全资子公司辽宁金旺设备安装工程服务有限公司（以下简称"辽宁金旺"）， 注册地为辽宁省锦州市七里河工业园区，注册资本为 300 万元，公司持股比例为 100%，已于 2023 年 9 月 4 日完成工商注册登记，并取得由锦州市义县市场监督 ...

Company Recognition and Structure - The company was recognized as a "2022 Liaoning Province Gazelle Enterprise" in January 2023[6]. - In the first half of 2023, the company established a controlling subsidiary, Liaoning Jiabao Intelligent Equipment Co., Ltd.[7]. - The company was awarded the title of "National Intellectual Property Demonstration Enterprise" by the National Intellectual Property Administration, valid for three years[7]. - The company has not undergone any registration changes during the reporting period[23]. - The company currently has 2 subsidiaries included in the consolidated financial statements, with 100% ownership of Liaoning Dianguan Technology Co., Ltd. and 60% ownership of Liaoning Jiabao Intelligent Equipment Co., Ltd.[72]. - The company has established stable partnerships with leading enterprises in the pharmaceutical and food sectors, enhancing its market reputation[45]. Financial Performance - The company's operating revenue for the current period is CNY 108,328,729.67, a decrease of 0.31% compared to the same period last year[26]. - The net profit attributable to shareholders decreased by 19.52% to CNY 18,682,202.93, while the net profit after deducting non-recurring items fell by 48.06% to CNY 10,999,736.36[26]. - The total assets increased by 7.12% to CNY 464,885,909.45, while total liabilities rose by 16.91% to CNY 177,746,582.01[27]. - The net cash flow from operating activities turned negative at CNY -16,065,084.02, a decline of 193.95% compared to the previous year[28]. - The gross profit margin decreased to 37.26% from 49.37% in the previous year, indicating a decline in profitability[26]. - The company’s weighted average return on equity based on net profit attributable to shareholders decreased to 6.41% from 21.35%[26]. - The company achieved operating revenue of 108.33 million yuan, a year-on-year decrease of 0.31%[39]. - The net profit attributable to shareholders was 18.68 million yuan, down 19.52% year-on-year[39]. - The company's cash and cash equivalents decreased by 26.97% from the previous year, indicating a tightening liquidity position[46]. Research and Development - The company has a total of 40 authorized patents, including 12 invention patents and 28 utility model patents, reflecting strong technological innovation capabilities[34]. - Research and development expenses decreased by 30.22% year-on-year to CNY 4.43 million, mainly due to a focus on self-directed R&D projects[55]. - The company is focusing on increasing R&D investment to ensure compliance with high-tech enterprise criteria and maintain tax incentives[76]. - The company is actively collaborating with domestic research institutions and universities to enhance packaging equipment technology[76]. Risks and Challenges - The company faces risks related to technology innovation, including the uncertainty of R&D outcomes and potential market misalignment, which could impact economic benefits[75]. - There is a risk of core technology leakage, which could adversely affect the company's competitive advantage, and measures are in place to protect intellectual property[75]. - The company has a risk of talent loss in the competitive food and pharmaceutical packaging equipment industry, with strategies to improve employee retention and attract new talent[75]. - Direct materials account for over 70% of the company's main business costs, exposing it to risks from fluctuations in raw material prices[77]. Shareholder and Equity Information - The total share capital of the company is 68,500,000 shares[22]. - The largest shareholder, Bi Chunguang, holds 18,301,266 shares, representing 26.72% of the total shares[106]. - The company has a concentrated shareholding structure, with the actual controller holding 46.57% of the shares, which may influence decision-making[77]. - The company distributed a total cash dividend of 13,700,000.00 yuan based on the 2022 annual profit distribution plan, with undistributed profits of 64,554,508.80 yuan attributable to the parent company[96]. Corporate Governance and Compliance - The company actively fulfills its corporate social responsibilities, ensuring the rights of employees, customers, suppliers, and other stakeholders while promoting sustainable development[73]. - There were no significant lawsuits or arbitration matters during the reporting period[81]. - The company has not reported any significant changes in major risks during the current period[77]. - The financial statements were approved by the board of directors on August 18, 2023[160]. Market and Industry Insights - The packaging equipment market in China was approximately 80.25 billion yuan in 2022, reflecting rapid growth[43]. - The global packaging equipment market is projected to reach 54.9 billion dollars by 2027, with a compound annual growth rate of 3.3%[42]. - The company operates in the specialized equipment manufacturing industry, particularly in food, beverage, and pharmaceutical equipment[21]. Accounting and Financial Reporting - The company follows the accrual basis of accounting and uses historical cost as the measurement basis for its financial statements[165]. - The company has not made any changes to its accounting policies compared to the previous year, ensuring consistency in financial reporting[154]. - The company has confirmed that there are no significant seasonal or cyclical characteristics affecting its operations, suggesting steady performance throughout the year[154].

证券代码：838810 证券简称：春光药装 公告编号：2023-041 辽宁春光制药装备股份有限公司 关于接待机构投资者调研情况的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 辽宁春光制药装备股份有限公司（以下简称"公司"）于 2023 年 5 月 10 日接待了 1 家机构的调研，现将主要情况公告如下： 一、 调研情况 调研时间：2023 年 5 月 10 日 调研地点：辽宁春光制药装备股份有限公司 调研形式：现场调研 调研机构：广发证券股份有限公司 上市公司接待人员：董事会秘书 金勇 二、 调研的主要问题及公司回复概要 问题 1：公司凭借哪些能力实现了入选国家第四批专精特新"小巨人"企业？ 回答：在公司董事长毕春光先生带领下，目前公司已建立起一支较为稳定的 长期从事包装装备研发的团队，公司拥有辽宁省制药包装装备专业技术创新中 心、辽宁省医药食品包装装备产学研联盟、辽宁春光制药装备股份有限公司企业 技术中心、辽宁省智能包装装备工程研究中心、辽宁春光制药装备股份有限公司 专家工作站——五大技术创 ...

证券代码：838810 证券简称：春光药装 公告编号：2023-039 一、 说明会类型 辽宁春光制药装备股份有限公司（以下简称"公司"）于 2023 年 4 月 24 日 在北京证券交易所指定信息披露平台（http://www.bse.cn/）发布了《辽宁春光制 药装备股份有限公司 2022 年年度报告》（公告编号：2023-026），为方便广大投 资者更深入了解公司 2022 年经营业绩的具体情况，加强与投资者的互动交流， 公司拟召开 2022 年年度报告业绩说明会。 二、 说明会召开的时间、地点 （一）会议召开时间：2023 年 5 月 4 日。 （二）会议召开地点 公司定于 2023 年 5 月 4 日（周四）15:00-17:00 在全景网举办 2022 年年度 报告业绩说明会，本次年报业绩说明会将采用网络远程的方式举行，投资者可登 陆全景网"投资者关系互动平台"（http://ir.p5w.net）参与本次年报业绩说明会。 三、 参加人员 公司董事长：毕春光先生 公司总经理：边境女士 公司财务负责人：陈蕾女士 公司董事会秘书：金勇先生 公司保荐代表人：孙贝洋先生 辽宁春光制药装备股份有限公司 20 ...